Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Prostate cancers with DNA damage response (DDR) gene alterations often exhibit aggressive behavior and poor survival.
• Poly (ADP-ribose) polymerase (PARP) enzyme inhibitors (PARPi) are effective in prostate cancers with BRCA1/2 mutations.
• The efficacy of PARPi in prostate cancers with other DNA repair gene alterations is under investigation.

Purpose of the Study:

• To review common genomic aberrations in prostate cancer DNA repair pathways.
• To discuss strategies for improving patient selection for PARPi therapy.
• To explore novel DNA repair pathway inhibitors and their potential to overcome treatment resistance.

Main Methods:

• Genomic analysis of prostate cancer DNA repair pathways.
• Literature review of current and emerging PARPi and other DNA repair inhibitors.
• Discussion of clinical development and patient stratification strategies.

Main Results:

• Identified frequent genomic aberrations in prostate cancer DNA repair pathways.
• Highlighted the need for refined patient selection criteria for PARPi treatment.
• Presented emerging therapeutic strategies targeting DNA repair pathways.

Conclusions:

• Targeting DNA repair pathways is a key strategy in advanced prostate cancer.
• Optimizing patient selection beyond BRCA1/2 mutations is crucial for PARPi efficacy.
• Novel inhibitors offer potential to address primary and secondary resistance in prostate cancer treatment.